An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial.
The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct.
The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to anti-psychotic medication.
During the trial, patients remained on their anti-psychotic medication and received doses of either cannabidiol or a placebo, the company said in a statement
GW is testing its cannabis drugs for a number of indications, including cancer-related pain and epilepsy.
Marijuana, which is the dried bud of the cannabis plant, is illegal under U.S. federal law but is allowed for medical use in about half the country’s states.
Interest in the medical effects of cannabis has been spurred recently by the legalization of recreational marijuana shops in Colorado and Canada’s move to create a federally regulated medical marijuana industry.
Cannabis As Medicine
2010-05-07I think that as we accept the medical utility of cannabis. We are going to start to dig more deeply in to the cannabinoids the key constituents of the marijuana…U.S. Surgeon General Calls for Cannabis Reclassification
2019-01-15The United States is at the forefront of the battle for cannabis legalization. Though more than 30 states have now legalized cannabis for medicinal use, the federal government still classifies…CBD For Dogs Becoming More Appealing to Pet Owners
2019-03-16CBD for dogs is becoming one of the more popular ways to keep man’s best friend in good health. Whether treating cancer or epilepsy, CBD may help dogs.
